New long-term data showed that the VenusP-valve delivered durable outcomes in patients undergoing percutaneous pulmonary ...

Off-label use of the Sapien and Sapien XT valves represents a “viable and durable option” for restoring pulmonary valve function in patients with right-ventricular outflow tract (RVOT) disorders, ...

DUBLIN, May 15, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced results from two late-breaking clinical trials presented virtually at the 2020 Society for Cardiovascular Angiography ...

Medtronic delivered new data from two clinical trials evaluating the long-term safety and shorter-term performance of its transcatheter pulmonary valve replacement therapies for children with ...

Most patients who undergo percutaneous pulmonary valve implantation for right ventricular outflow tract (RVOT) dysfunction achieve acute hemodynamic benefit within 1 month that is sustained out to at ...

July 23, 2009 (Gaithersburg, Maryland) — The FDA Circulatory System Devices Panel voted 12 to 0 to recommend approval of a transcatheter pulmonary valve for use under humanitarian device exemption ...

Biventricular correction of tetralogy of Fallot was devised more than 50 years ago. Current short-term outcomes are excellent. The potential for late complications is, however, an important concern ...

Significant improvements in a number of quality of life measures occurred in a cohort of patients who underwent percutaneous pulmonary valve implantation for dysfunctional pulmonary valve conduits.

Milestone Results Presented as Late-Breaking Clinical Science at SCAI 2020 DUBLIN, May 15, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced results from two late-breaking clinical ...